ResultsIQ

ResultsIQ › Latest results › Zim Laboratories Limited

Zim Laboratories Limited Q2 FY26 earnings call summary

NSE: ZIMLAB · BSE: 541400

Earnings call of 14 Nov 2025, summarised by AI from the filing.

ZIM Laboratories Q2 FY26 operating income ₹887 million, up 23.6% sequentially; FY26 revenue and EBITDA guided broadly in line with FY25.

Key takeaways

  1. FY26 guidance FY26 revenues and EBITDA expected broadly in line with FY25; margins to remain constant in Q3 and Q4.
  2. EU-GMP timeline EU-GMP audit targeted by March '26, supplies resuming Q1 or Q2 FY27; CAPA accepted by assessor.
  3. Site transfers Tamsulosin + Dutasteride transfer to PGA-approved site; commercial supplies expected within 6 months.
  4. Nutra decline Nutraceutical revenue declined due to deferment of domestic institutional orders; recovery expected in Q3 and Q4.

Original filing on BSE

Zim Laboratories Limited Q1 FY27 results

As filed: Revenue ₹94.2 cr (+31% year on year), EBITDA ₹2.5 cr (−51% year on year), PAT −₹4.0 cr, EBITDA margin 2.6% (−434 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹105 cr (−3% year on year), EBITDA ₹7.2 cr (−49% year on year), PAT ₹3.7 cr (−25% year on year), EBITDA margin 6.8% (−601 bps). Score 21 of 100, Below trend. Revenue growth was below the company's own trend; EBITDA growth was well below it; profit growth was in line with it. EBITDA margin fell 601 bps year on year. Other income 125% of PBT. Revenue fell 3% from last quarter. Share price after the results: +13.3% in 30 days (Nifty 500: +3.0%).
  • Q3 FY26: Revenue ₹109 cr (+13% year on year), EBITDA ₹12.8 cr (+7% year on year), PAT ₹4.4 cr (+10% year on year), EBITDA margin 11.8% (−71 bps). Score 59 of 100, In line with trend. Revenue growth was above the company's own trend; EBITDA and profit growth were in line with it. EBITDA margin fell 71 bps year on year. Other income 28% of PBT. Revenue grew on the previous quarter, against its usual seasonal pattern. Share price after the results: −13.1% in 30 days (Nifty 500: −10.1%).
  • Q2 FY26: Revenue ₹89.0 cr (−3% year on year), EBITDA ₹6.0 cr (−40% year on year), PAT ₹0.0 cr (−100% year on year), EBITDA margin 6.7% (−413 bps). Score 20 of 100, Below trend. Revenue and profit growth were below the company's own trend; EBITDA growth was well below it. EBITDA margin fell 413 bps year on year. Share price after the results: −4.5% in 30 days (Nifty 500: −0.5%).
  • Q1 FY26: Revenue ₹72.0 cr (−12% year on year), EBITDA ₹5.0 cr (−38% year on year), PAT −₹2.0 cr (−300% year on year), EBITDA margin 6.9% (−281 bps). Score 12 of 100, Below trend. Revenue, EBITDA and profit growth were well below the company's own trend. EBITDA margin fell 281 bps year on year. Revenue fell 34% from last quarter. Share price after the results: −8.9% in 29 days (Nifty 500: +0.6%).
  • Q4 FY25: Revenue ₹109 cr (−8% year on year), EBITDA ₹14.0 cr (−7% year on year), PAT ₹5.0 cr (−38% year on year), EBITDA margin 12.8% (+13 bps). Score 25 of 100, Below trend. Revenue and profit growth were well below the company's own trend; EBITDA growth was below it. EBITDA margin rose 13 bps year on year. Tax rate 38%. Share price after the results: +11.6% in 30 days (Nifty 500: +0.8%).
  • Q3 FY25: Revenue ₹96.0 cr (0% year on year), EBITDA ₹12.0 cr (0% year on year), PAT ₹4.0 cr (−20% year on year), EBITDA margin 12.5% (0 bps). Score 30 of 100, Below trend. Revenue and EBITDA growth were below the company's own trend. EBITDA margin was flat year on year. Other income 33% of PBT.
  • Q2 FY25: Revenue ₹92.0 cr (+7% year on year), EBITDA ₹10.0 cr (+11% year on year), PAT ₹2.0 cr (−50% year on year), EBITDA margin 10.9% (+40 bps). Score 24 of 100, Below trend. EBITDA margin rose 40 bps year on year. Other income 33% of PBT. Tax rate 0%. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Zim Laboratories Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.